UY26495A1 - " derivados de tiazolilamida" - Google Patents

" derivados de tiazolilamida"

Info

Publication number
UY26495A1
UY26495A1 UY26495A UY26495A UY26495A1 UY 26495 A1 UY26495 A1 UY 26495A1 UY 26495 A UY26495 A UY 26495A UY 26495 A UY26495 A UY 26495A UY 26495 A1 UY26495 A1 UY 26495A1
Authority
UY
Uruguay
Prior art keywords
thiazolylamide
derivatives
thiazolylamide derivatives
drugs
preparation
Prior art date
Application number
UY26495A
Other languages
English (en)
Inventor
Dr Rudiger Fischer
Dr Gerard Kleymann
Dr Ulrich Betz
Dr Judith Baumeister
Dr Wolfgang Bender
Dr Peter Eckenberg
Dr Gabriele Handke
Dr Martin Hendrix
Dr Kerstin Henninger
Dr Axel Jensen
Dr Jorg Keldenich
Dr Udo Schneider
Dr Olaf Weber
Dr Gerald Kleymann
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19962532A external-priority patent/DE19962532A1/de
Priority claimed from DE10039265A external-priority patent/DE10039265A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of UY26495A1 publication Critical patent/UY26495A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a nuevos compuestos, a un procedimiento para su preparación así como a su uso como medicamentos, especialmente como medicamentos antivíricos.
UY26495A 1999-12-23 2000-12-20 " derivados de tiazolilamida" UY26495A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19962532A DE19962532A1 (de) 1999-12-23 1999-12-23 Thiazolylamid-Derivate
DE10039265A DE10039265A1 (de) 2000-08-11 2000-08-11 Thiazolylamid-Derivate

Publications (1)

Publication Number Publication Date
UY26495A1 true UY26495A1 (es) 2001-07-31

Family

ID=26006669

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26495A UY26495A1 (es) 1999-12-23 2000-12-20 " derivados de tiazolilamida"

Country Status (27)

Country Link
US (1) US7105553B2 (es)
EP (1) EP1244641B1 (es)
JP (1) JP4726175B2 (es)
KR (1) KR100768361B1 (es)
CN (1) CN1235890C (es)
AR (1) AR029210A1 (es)
AT (1) ATE293104T1 (es)
AU (1) AU784286B2 (es)
BR (1) BR0017030B8 (es)
CA (1) CA2396720C (es)
CO (1) CO5261491A1 (es)
DE (1) DE50010060D1 (es)
DK (1) DK1244641T3 (es)
DO (1) DOP2000000109A (es)
ES (1) ES2240233T3 (es)
HK (1) HK1057552A1 (es)
IL (2) IL149897A0 (es)
MX (1) MXPA02006243A (es)
MY (1) MY134880A (es)
NZ (1) NZ519701A (es)
PE (1) PE20010964A1 (es)
PL (1) PL208707B1 (es)
PT (1) PT1244641E (es)
SV (1) SV2002000249A (es)
TW (1) TWI256951B (es)
UY (1) UY26495A1 (es)
WO (1) WO2001047904A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2000259734A1 (en) * 2000-06-15 2001-12-24 Gerald Kleymann Method for identifying compounds with anti-herpes activity
DE10129714A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE10131128A1 (de) * 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
AR036873A1 (es) 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
EP2179744B1 (en) * 2004-09-09 2010-12-01 Novartis Vaccines and Diagnostics GmbH Decreasing potential latrogenic risks associated with influenza vaccines
DE102005014248A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
WO2007130075A1 (en) * 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2007019397A2 (en) * 2005-08-05 2007-02-15 Genelabs Technologies, Inc. 6-membered aryl and heteroaryl derivatives for the treatment of hepatitis c virus
KR20080090381A (ko) * 2005-08-29 2008-10-08 제라드 엠. 하우지 테라뮤틴 조절물질
NZ595770A (en) * 2006-03-17 2013-04-26 Univ Johns Hopkins N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
US20100051879A1 (en) * 2006-11-22 2010-03-04 The Regents od the Univesity of California Functionalized Boron Nitride Nanotubes
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
SG11201506153TA (en) * 2013-02-12 2015-09-29 Aicuris Gmbh & Co Kg Helicase-primase inhibitors for use in a method of treating alzheimer's disease
MX2017000059A (es) * 2014-07-07 2017-11-08 Prophylaxis LLC Metodos de tratamiento profilactico antivirales y kits de profilaxis previa a la exposicion.
TWI706940B (zh) 2016-04-06 2020-10-11 德商創新分子有限責任公司 新穎之抗病毒化合物
CN117186084A (zh) 2016-11-28 2023-12-08 艾库里斯有限及两合公司 普瑞利韦磺酸盐、其药物制剂、制造方法及治疗疱疹病毒的用途
PL3544976T3 (pl) * 2016-11-28 2021-11-02 Aicuris Gmbh & Co. Kg Hemihydrat wolnej zasady n-[5-(aminosulfonylo)-4-metylo-1,3-tiazol-2-ilo]-n-metylo-2-[4-(2-pirydynylo)fenylo]acetamidu, sposoby jego wytwarzania i zastosowania
TW201825095A (zh) 2016-11-28 2018-07-16 德商艾庫里斯抗感染治療有限公司 包含n-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺之局部醫藥調配物
EP3566749A4 (en) * 2017-01-09 2020-09-23 Medshine Discovery Inc. THIAZOLE DERIVATIVE AND USES OF IT
FI3692039T3 (fi) 2017-10-05 2023-03-23 Innovative Molecules Gmbh Substituoitujen tiatsolien enantiomeerejä virusten vastaisina yhdisteinä
CN112384512B (zh) * 2018-07-06 2022-03-29 辉诺生物医药科技（杭州）有限公司 噻唑类化合物的晶型及其应用
KR20220160024A (ko) 2020-03-26 2022-12-05 아이쿠리스 게엠베하 운트 코. 카게 N-[5-(아미노술포닐)-4-메틸-1,3-티아졸-2-일]-n-메틸-2-[4-(2-피리디닐)페닐]아세트아미드 반수화물을 포함하는 안과용 제제
EP3925595A1 (en) 2020-06-17 2021-12-22 AiCuris GmbH & Co. KG Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl] acetamide hemihydrate
WO2022090409A1 (en) 2020-10-29 2022-05-05 Innovative Molecules Gmbh Deuterated aminothiazole compounds as antiviral compounds
WO2023135303A1 (en) 2022-01-17 2023-07-20 Innovative Molecules Gmbh Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof
WO2024049760A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Cyclic urea thiazolyl compounds for treatment of hsv
WO2024047508A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus
WO2024047507A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. A novel crystalline form of pritelivir
WO2024047506A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. A novel crystalline form of pritelivir

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2075560A5 (es) * 1970-01-16 1971-10-08 Shell Int Research
US3658830A (en) 1970-01-16 1972-04-25 Shell Oil Co 5-(substituted mercapto sulfiny sulfonyl or sulfamoyl)
US3717651A (en) 1970-04-20 1973-02-20 Shell Oil Co Thiazoles
US3847588A (en) 1970-04-20 1974-11-12 Shell Oil Co Thiazoles herbicidal
CZ207298A3 (cs) 1995-12-29 1998-11-11 Boehringer Ingelheim Pharmaceuticals, Inc. Fenylthiazolové deriváty, způsob výroby a farmaceutický prostředek
US5705344A (en) 1996-03-14 1998-01-06 Tularik, Inc. High-throughput screening assay for inhibitors of nucleic acid helicases
GB2311069A (en) 1996-03-14 1997-09-17 Merck & Co Inc Primase isolated from human cytomegalovirus (HCMV)
GB2311068A (en) 1996-03-14 1997-09-17 Merck & Co Inc Helicase isolated from human cytomegalovirus (HCMV)
CA2223032A1 (en) 1997-02-21 1998-08-21 Smithkline Beecham Corporation Use of hsv-1 ul-15 and vp5 in identifying anti-viral agents
DE19802437A1 (de) 1998-01-23 1999-07-29 Bayer Ag Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
WO1999042455A1 (en) 1998-02-19 1999-08-26 Tularik Inc. Antiviral agents
EP1064273B1 (en) 1998-03-19 2002-12-18 PHARMACIA & UPJOHN COMPANY 1,3,4-thiadiazoles useful for the treatment of cmv infections
DE50008597D1 (de) 1999-03-08 2004-12-16 Bayer Healthcare Ag Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel

Also Published As

Publication number Publication date
PL356484A1 (en) 2004-06-28
HK1057552A1 (en) 2004-04-08
EP1244641A1 (de) 2002-10-02
ES2240233T3 (es) 2005-10-16
JP4726175B2 (ja) 2011-07-20
PE20010964A1 (es) 2001-11-10
DK1244641T3 (da) 2005-07-11
AU3157401A (en) 2001-07-09
MY134880A (en) 2007-12-31
BR0017030A (pt) 2003-01-07
BR0017030B1 (pt) 2013-10-01
AR029210A1 (es) 2003-06-18
JP2003519134A (ja) 2003-06-17
ATE293104T1 (de) 2005-04-15
CN1434812A (zh) 2003-08-06
IL149897A (en) 2008-08-07
PL208707B1 (pl) 2011-05-31
DOP2000000109A (es) 2002-08-30
WO2001047904A1 (de) 2001-07-05
MXPA02006243A (es) 2003-01-28
PT1244641E (pt) 2005-08-31
US7105553B2 (en) 2006-09-12
EP1244641B1 (de) 2005-04-13
CO5261491A1 (es) 2003-03-31
DE50010060D1 (de) 2005-05-19
US20040006076A1 (en) 2004-01-08
AU784286B2 (en) 2006-03-02
SV2002000249A (es) 2002-06-07
KR20020067568A (ko) 2002-08-22
NZ519701A (en) 2004-05-28
IL149897A0 (en) 2002-11-10
BR0017030B8 (pt) 2021-05-25
CA2396720A1 (en) 2001-07-05
CA2396720C (en) 2009-09-22
KR100768361B1 (ko) 2007-10-18
CN1235890C (zh) 2006-01-11
TWI256951B (en) 2006-06-21

Similar Documents

Publication Publication Date Title
UY26495A1 (es) " derivados de tiazolilamida"
MX9304819A (es) Nuevos derivados de xantina y procedimiento para su preparacion.
UY27098A1 (es) Derivados de indol
GT199900055A (es) Nuevas dihidropirimidinas2 heterocìclicamente sustituidas.
UY27571A1 (es) 2-tio-3, 5-diciano-4-fenil-6-aminopiridinas sustituidas y su uso
DOP2002000433A (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituidas y su uso
ES2172937T3 (es) 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.
BR0114903A (pt) 7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação
SV1999000060A (es) Procedimiento para la preparacion de (s,s)-bencil-2,8-diazabiciclo 4.3.0 nonano ref. 32965-sv
BRPI9914571B8 (pt) composto, processo para sua preparação, uso do mesmo, bem como composição farmacêutica.
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
CO5011066A1 (es) Compuestos de triazina
AR023979A1 (es) Procesos para preparar compuestos intermedios de plaguicidas
ECSP045271A (es) Derivados de quinolina
ID27733A (id) Metoksiminofenilasetamida
ECSP003843A (es) Derivados de tiazolilamida
AR021616A1 (es) Cicloheptenos sustituidos, procedimiento para su preparacion y uso de los mismos.
UY26435A1 (es) Compuestos bis-básicos como inhibidores de triptasa, procedimiento para su preparación y su utilización como medicamentos.
AR025073A1 (es) Proceso para la preparacion de compuestos de 1,3-dicarbonilo acilados
BR0213329A (pt) Processo para preparação de 14beta-hidróxi-baccatin iii-1,14carbonato
ITMI20022534A1 (it) Procedimento per la preparazione di terbinafina mediante l'uso di platino come catalizzatore.
MXPA04001856A (es) Indan-1-oles c2-sustituidos y sus derivados, metodo para su produccion y su uso como medicamentos.
MXPA04001852A (es) Uso de sistemas indan-1-ol c2-sustituidas para la produccion de medicamentos para la profilaxis o tratamiento de obesidad.
ECSP972189A (es) Nuevas triazolopurinas, procedimientos para su preparacion y su empleo como medicamentos
GT199900057A (es) Procedimiento para la preparaciòn de ( s , s ) - bencil - 2,8 - diazabiciclo 4.3.0. nonano.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20161107